Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03386721 |
| Consolidated Lead Sponsor | Roche / Genentech |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 256 participants (ACTUAL) |
| Registered Start Date | 2018-02-19 |
| WhyStopped Classification | Safety / Toxicity / Adverse Events |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | Open Hospital Dossier -> |
| UZ Antwerpen | Edegem, Belgium | Open Hospital Dossier -> |
| UZ Gent | Ghent, Belgium | Open Hospital Dossier -> |
| Institut Bergonie | Bordeaux, France | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.